MARKET

ANAB

ANAB

Anaptysbio Inc
NASDAQ
44.35
+1.05
+2.42%
After Hours: 44.35 0 0.00% 17:01 12/05 EST
OPEN
43.60
PREV CLOSE
43.30
HIGH
44.84
LOW
43.60
VOLUME
357.82K
TURNOVER
--
52 WEEK HIGH
45.32
52 WEEK LOW
12.21
MARKET CAP
1.23B
P/E (TTM)
-15.7348
1D
5D
1M
3M
1Y
5Y
1D
AnaptysBio (ANAB): Assessing Valuation After Legal Battle Over Jemperli Royalties and Future Cash Flows Escalates
Simply Wall St · 16h ago
Jemperli Royalty Dispute Could Be a Game Changer for AnaptysBio (ANAB)
Simply Wall St · 4d ago
Quality stocks present “once in a generation” opportunity – top stocks as per SA Quant
Seeking Alpha · 4d ago
Weekly Report: what happened at ANAB last week (1124-1128)?
Weekly Report · 5d ago
A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus
Simply Wall St · 11/28 07:20
AnaptysBio Files Legal Complaint Against GSK and Tesaro
TipRanks · 11/26 21:42
AnaptysBio And Tesaro/GSK File Competing Delaware Lawsuits Alleging Breaches Of Their Collaboration And License Agreement
Benzinga · 11/26 21:05
ANAPTYSBIO INC - ON NOV 26, TESARO & GSK PUBLICLY FILED THEIR COMPLAINT AGAINST CO ALLEGING BREACHED COLLABORATION AGREEMENT
Reuters · 11/26 21:04
More
About ANAB
AnaptysBio, Inc. is a clinical-stage biotechnology company. The Company is focused on delivering immunology therapeutics for autoimmune and inflammatory diseases. The Company’s lead program, Rosnilimab, is a depleter and agonist targeting PD-1+ T cells, is in a Phase IIb trial for the treatment of rheumatoid arthritis and in a Phase II trial for the treatment of ulcerative colitis. The Company’s pipeline also includes ANB033, a CD122 antagonist, and ANB101, a blood dendritic cell antigen 2 (BDCA2) modulator, in Phase I trials. It has also discovered multiple therapeutic antibodies licensed to GSK in a financial collaboration for immuno-oncology, including a PD-1 antagonist (Jemperli (dostarlimab-gxly)) and a TIM-3 antagonist (cobolimab, GSK4069889). Rosnilimab is an IgG1 antibody that directly targets PD-1+ T cells, resulting in their depletion or agonism, impacting pathogenic drivers of autoimmune and inflammatory diseases.

Webull offers AnaptysBio Inc stock information, including NASDAQ: ANAB real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ANAB stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading ANAB stock methods without spending real money on the virtual paper trading platform.